Donato A Di Monte

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6365841/publications.pdf

Version: 2024-02-01

132 papers	13,283 citations	15495 65 h-index	22147 113 g-index
141 all docs	141 docs citations	141 times ranked	11539 citing authors

#	Article	IF	Citations
1	Sphingolipid changes in Parkinson L444P <i>GBA</i> mutation fibroblasts promote Î±-synuclein aggregation. Brain, 2022, 145, 1038-1051.	3.7	30
2	The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic Î±-Synuclein Spread in Rodent Models of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1463-1478.	1.5	2
3	Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinsonâ€™s disease. Cell Death and Differentiation, 2021, 28, 1720-1732.	5.0	6
4	The transcription factor BCL11A defines distinct subsets of midbrain dopaminergic neurons. Cell Reports, 2021, 36, 109697.	2.9	14
5	Inhibition of microglial Î²-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons. Journal of Neuroinflammation, 2021, 18, 220.	3.1	11
6	Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease. International Review of Movement Disorders, 2021, 2, 155-191.	0.1	0
7	Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular Î±-synuclein transfer. Journal of Clinical Investigation, 2019, 129, 3738-3753.	3.9	126
8	Longâ€lasting pathological consequences of overexpressionâ€induced Î±â€synuclein spreading in the rat brain. Aging Cell, 2018, 17, e12727.	3.0	25
9	In vivo models of alpha-synuclein transmission and propagation. Cell and Tissue Research, 2018, 373, 183-193.	1.5	51
10	Phosphorylation of Parkin at serine 65 is essential for its activation<i>in vivo</i>. Open Biology, 2018, 8, 180108.	1.5	81
11	Activation of the DNA damage response in vivo in synucleinopathy models of Parkinsonâ€™s disease. Cell Death and Disease, 2018, 9, 818.	2.7	85
12	LRRK2 kinase regulates Î±-synuclein propagation via RAB35 phosphorylation. Nature Communications, 2018, 9, 3465.	5.8	121
13	Mesenchymal stromal SB623 cell implantation mitigates nigrostriatal dopaminergic damage in a mouse model of Parkinson's disease. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 1835-1843.	1.3	5
14	Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP. Trends in Pharmacological Sciences, 2017, 38, 541-555.	4.0	58
15	Brain-to-stomach transfer of Î±-synuclein via vagal preganglionic projections. Acta Neuropathologica, 2017, 133, 381-393.	3.9	148
16	The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain, 2017, 140, 2706-2721.	3.7	52
17	Pesticides and Parkinson's Disease: Current Experimental and Epidemiological Evidence. Advances in Neurotoxicology, 2017, 1, 83-117.	0.7	15
18	Brain propagation of transduced Î±-synuclein involves non-fibrillar protein species and is enhanced in Î±-synuclein null mice. Brain, 2016, 139, 856-870.	3.7	78

#	ARTICLE	IF	CITATIONS
19	Overview of Neurodegenerative Disorders and Susceptibility Factors in Neurodegenerative Processes. , 2015, , 197-210.		1
20	Neuron-to-neuron Î±-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathologica Communications, 2015, 3, 13.	2.4	75
21	Function and developmental origin of a mesocortical inhibitory circuit. Nature Neuroscience, 2015, 18, 872-882.	7.1	43
22	Metformin lowers Ser-129 phosphorylated Î±-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death and Disease, 2014, 5, e1209-e1209.	2.7	116
23	Neurodegeneration by Activation of the Microglial Complement-Phagosome Pathway. Journal of Neuroscience, 2014, 34, 8546-8556.	1.7	192
24	Evidence of oxidative stress in young and aged DJâ€1â€deficient mice. FEBS Letters, 2013, 587, 1562-1570.	1.3	14
25	Oxidative and nitrative alphaâ€synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. Journal of Neurochemistry, 2013, 125, 491-511.	2.1	116
26	Î±-Synuclein Elevation in Human Neurodegenerative Diseases: Experimental, Pathogenetic, and Therapeutic Implications. Molecular Neurobiology, 2013, 47, 484-494.	1.9	45
27	Caudoâ€rostral brain spreading of Î±â€synuclein through vagal connections. EMBO Molecular Medicine, 2013, 5, 1119-1127.	3.3	223
28	Increased Î±-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death and Disease, 2012, 3, e315-e315.	2.7	58
29	Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 49-63.	1.5	57
30	Lysosomal Degradation of Î±-Synuclein in Vivo. Journal of Biological Chemistry, 2010, 285, 13621-13629.	1.6	298
31	Î±-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra. PLoS ONE, 2010, 5, e12122.	1.1	138
32	Serine 129 Phosphorylation Reduces the Ability of Î±-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo. Journal of Biological Chemistry, 2010, 285, 17648-17661.	1.6	105
33	Geneâ€“environment interactions in Parkinson's disease and other forms of parkinsonism. NeuroToxicology, 2010, 31, 598-602.	1.4	63
34	Methionine oxidation stabilizes non-toxic oligomers of Î±-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 322-330.	1.8	85
35	Decreased Î±-synuclein expression in the aging mouse substantia nigra. Experimental Neurology, 2009, 220, 359-365.	2.0	39
36	Enhanced &#945;-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications. Current Protein and Peptide Science, 2009, 10, 476-482.	0.7	23

#	ARTICLE	IF	CITATIONS
37	Pathologic Modifications of Î±-Synuclein in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Treated Squirrel Monkeys. Journal of Neuropathology and Experimental Neurology, 2008, 67, 793-802.	0.9	68
38	MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology. PLoS ONE, 2008, 3, e1616.	1.1	230
39	Paraquat Neurotoxicity Is Mediated by a Bak-dependent Mechanism. Journal of Biological Chemistry, 2008, 283, 3357-3364.	1.6	102
40	Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinsonâ€™s Disease. Journal of Immunology, 2008, 181, 7194-7204.	0.4	113
41	Paraquat Exposure Reduces Nicotinic Receptor-Evoked Dopamine Release in Monkey Striatum. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 124-129.	1.3	10
42	Letter regarding: â€œParaquat: The Red Herring of Parkinson's Disease Researchâ€• Toxicological Sciences, 2008, 103, 215-216.	1.4	10
43	Paraquat-induced Neurodegeneration: a Model of Parkinson's Disease Risk Factors. , 2008, , 207-217.		1
44	Effect of 4-Hydroxy-2-nonenal Modification on Î±-Synuclein Aggregation. Journal of Biological Chemistry, 2007, 282, 5862-5870.	1.6	166
45	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	0.9	104
46	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	0.9	41
47	Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiology of Aging, 2007, 28, 907-913.	1.5	127
48	Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Experimental Neurology, 2007, 204, 619-630.	2.0	120
49	The selective Îº-opioid receptor agonist U50,488 reduces l-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Experimental Neurology, 2007, 205, 101-107.	2.0	38
50	Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration. Journal of Neuroscience, 2007, 27, 8138-8148.	1.7	346
51	Nicotine reduces levodopaâ€•induced dyskinesias in lesioned monkeys. Annals of Neurology, 2007, 62, 588-596.	2.8	124
52	Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to Î±6Î²2* nAChRs. Journal of Neurochemistry, 2007, 100, 180-190.	2.1	52
53	Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Research, 2007, 1140, 188-194.	1.1	36
54	Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiology of Disease, 2007, 25, 392-400.	2.1	217

#	Article	IF	Citations
55	Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Experimental Neurology, 2006, 202, 434-440.	2.0	24
56	Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience, 2006, 141, 929-937.	1.1	64
57	Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of Neurochemistry, 2006, 98, 1866-1875.	2.1	113
58	Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Annals of Neurology, 2006, 60, 256-260.	2.8	99
59	Nigrostriatal Dopaminergic Neurodegeneration in the Weaver Mouse Is Mediated via Neuroinflammation and Alleviated by Minocycline Administration. Journal of Neuroscience, 2006, 26, 11644-11651.	1.7	47
60	The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. Journal of Neuroscience Methods, 2005, 145, 159-166.	1.3	31
61	Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. Journal of Neurochemistry, 2005, 93, 1030-1037.	2.1	229
62	Toxicity of Redox Cycling Pesticides in Primary Mesencephalic Cultures. Antioxidants and Redox Signaling, 2005, 7, 649-653.	2.5	53
63	Redox cycling of the herbicide paraquat in microglial cultures. Molecular Brain Research, 2005, 134, 52-56.	2.5	140
64	Î±-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiology of Disease, 2005, 20, 898-906.	2.1	111
65	Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology, 2005, 48, 398-405.	2.0	14
66	Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys. Neuroscience, 2005, 132, 409-420.	1.1	48
67	Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 770-777.	1.3	46
68	Aging of the nigrostriatal system in the squirrel monkey. Journal of Comparative Neurology, 2004, 471, 387-395.	0.9	105
69	Dopamine and Lâ€dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB Journal, 2004, 18, 962-964.	0.2	220
70	The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurology, The, 2003, 2, 531-538.	4.9	320
71	Effects of <scp>l</scp>â€dopa and other amino acids against paraquatâ€induced nigrostriatal degeneration. Journal of Neurochemistry, 2003, 85, 82-86.	2.1	119
72	Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. European Journal of Neuroscience, 2003, 18, 589-600.	1.2	260

#	ARTICLE	IF	CITATIONS
73	Nuclear Localization of Î±-Synuclein and Its Interaction with Histonesâ€. Biochemistry, 2003, 42, 8465-8471.	1.2	299
74	Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Experimental Neurology, 2003, 183, 173-179.	2.0	8
75	Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo. Neuron, 2003, 37, 899-909.	3.8	594
76	Î±-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration. Journal of Neuroscience, 2003, 23, 3095-3099.	1.7	225
77	Behavioral and Neurochemical Effects of Wild-Type and Mutated Human Î±-Synuclein in Transgenic Mice. Experimental Neurology, 2002, 175, 35-48.	2.0	255
78	Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat. Neurobiology of Disease, 2002, 10, 119-127.	2.1	706
79	The Herbicide Paraquat Causes Up-regulation and Aggregation of Î±-Synuclein in Mice. Journal of Biological Chemistry, 2002, 277, 1641-1644.	1.6	566
80	Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience, 2002, 113, 213-220.	1.1	37
81	l-DOPA Does Not Cause Neurotoxicity in VMAT2 Heterozygote Knockout Mice. NeuroToxicology, 2002, 23, 611-619.	1.4	20
82	Environmental Factors in Parkinsonâ€™s Disease. NeuroToxicology, 2002, 23, 487-502.	1.4	213
83	Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. Journal of Neurochemistry, 2002, 83, 167-175.	2.1	85
84	Mechanistic Approaches to Parkinson's Disease Pathogenesis. Brain Pathology, 2002, 12, 499-510.	2.1	115
85	Lack of Nigral Pathology in Transgenic Mice Expressing Human Î±-Synuclein Driven by the Tyrosine Hydroxylase Promoter. Neurobiology of Disease, 2001, 8, 535-539.	2.1	273
86	Acute exposure to organochlorine pesticides does not affect striatal dopamine in mice. Neurotoxicity Research, 2001, 3, 537-543.	1.3	8
87	Levodopa induces dyskinesias in normal squirrel monkeys. Annals of Neurology, 2001, 50, 254-257.	2.8	64
88	Nicotine administration reduces striatal MPP+ levels in mice. Brain Research, 2001, 917, 219-224.	1.1	27
89	The role of environmental agents in Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 419-426.	0.8	29
90	Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Movement Disorders, 2000, 15, 459-466.	2.2	162

#	ARTICLE	IF	CITATIONS
91	Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Research, 2000, 885, 283-288.	1.1	119
92	Autoradiographic analysis of dopamine receptor-stimulated [35S]GTPÎ³S binding in rat striatum. Brain Research, 2000, 885, 133-136.	1.1	11
93	Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience, 2000, 98, 263-273.	1.1	73
94	Autoradiographic analysis of N-methyl-d-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Levodopa treatment. Neuroscience, 2000, 99, 697-704.	1.1	14
95	Impaired Glutamate Clearance as a Consequence of Energy Failure Caused by MPP+ in Astrocytic Cultures. Toxicology and Applied Pharmacology, 1999, 158, 296-302.	1.3	37
96	7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Research, 1999, 839, 41-48.	1.1	30
97	Novel Î±-Synuclein-Immunoreactive Proteins in Brain Samples from the Contursi Kindred, Parkinson's, and Alzheimer's Disease. Experimental Neurology, 1998, 154, 684-690.	2.0	48
98	Inhibition of Monoamine Oxidase Contributes to the Protective Effect of 7â€Nitroindazole Against MPTP Neurotoxicity. Journal of Neurochemistry, 1997, 69, 1771-1773.	2.1	78
99	Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of l-DOPA-treated monkeys. Brain Research, 1996, 738, 53-59.	1.1	71
100	Role of Nitric Oxide in Methamphetamine Neurotoxicity: Protection by 7â€Nitroindazole, an Inhibitor of Neuronal Nitric Oxide Synthase. Journal of Neurochemistry, 1996, 67, 2443-2450.	2.1	86
101	Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia, 1995, 15, 203-206.	2.5	44
102	Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain. Brain Research, 1994, 647, 249-254.	1.1	6
103	Rapid ATP Loss Caused by Methamphetamine in the Mouse Striatum: Relationship Between Energy Impairment and Dopaminergic Neurotoxicity. Journal of Neurochemistry, 1994, 62, 2484-2487.	2.1	116
104	PCR Analysis of platelet mtDNA: Lack of specific changes in Parkinson's disease. Movement Disorders, 1993, 8, 74-82.	2.2	30
105	Chapter 36: Astrocytes and Parkinson's disease. Progress in Brain Research, 1992, 94, 429-436.	0.9	166
106	Role of Astrocytes in MPTP Metabolism and Toxicity. Annals of the New York Academy of Sciences, 1992, 648, 219-228.	1.8	19
107	MPTP-Induced ATP Loss in Mouse Brain. Annals of the New York Academy of Sciences, 1992, 648, 306-308.	1.8	9
108	Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Archives of Biochemistry and Biophysics, 1992, 295, 132-136.	1.4	72

#	ARTICLE	IF	CITATIONS
109	The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Research, 1992, 572, 224-231.	1.1	89
110	Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia, 1992, 5, 48-55.	2.5	27
111	Glutathione in Parkinson's disease: A link between oxidative stress and mitochondrial damage?. Annals of Neurology, 1992, 32, S111-S115.	2.8	98
112	Blood lactate in Parkinson's disease. Annals of Neurology, 1991, 29, 342-343.	2.8	8
113	Effects of 1-Methyl-4-Phenyl- 1,2,3,6-Tetrahydropyridine and 1 -Methyl-4-Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes. Journal of Neurochemistry, 1990, 54, 1295-1301.	2.1	84
114	The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Research, 1990, 531, 242-252.	1.1	62
115	Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes. Archives of Biochemistry and Biophysics, 1990, 282, 358-362.	1.4	134
116	Commentary on â€˜Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)â€™. Toxicology Letters, 1989, 48, 117-119.	0.4	1
117	The biodisposition of MPP+ in mouse brain. Neuroscience Letters, 1989, 101, 83-88.	1.0	30
118	Diethyldithiocarbamate and disulfiram inhibit MPP+ and dopamine uptake by striatal synaptosomes. European Journal of Pharmacology, 1989, 166, 23-29.	1.7	5
119	Relationships between intracellular vitamin E, lipid peroxidation, and chemical toxicity in hepatocytes. Toxicology and Applied Pharmacology, 1988, 93, 288-297.	1.3	66
120	Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes. Biochemical and Biophysical Research Communications, 1988, 153, 734-740.	1.0	48
121	Role of Active Oxygen in Paraquat and 1-Methyl-4-phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Cytotoxicity. , 1988, 49, 795-801.		5
122	Comparative toxicity and antioxidant activity of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes. Archives of Biochemistry and Biophysics, 1987, 255, 14-18.	1.4	11
123	Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochemical and Biophysical Research Communications, 1987, 148, 153-160.	1.0	32
124	VI. Studies on the mechanism of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine cytotoxicity in isolated hepatocytes. Life Sciences, 1987, 40, 741-748.	2.0	33
125	Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes. Chemico-Biological Interactions, 1987, 62, 105-116.	1.7	27
126	Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochemical and Biophysical Research Communications, 1986, 137, 303-309.	1.0	143

#	ARTICLE	IF	CITATIONS
127	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochemical and Biophysical Research Communications, 1986, 137, 310-315.	1.0	165
128	Decreased hepatic glutathione in chronic alcoholic patients. Journal of Hepatology, 1986, 3, 1-6.	1.8	87
129	tertâ€“butylhydroperoxideâ€"Induced toxicity in isolated hepatocytes: Contribution of thiol oxidation and lipid peroxidation. Journal of Biochemical Toxicology, 1986, 1, 13-22.	0.5	44
130	Induction of cell damage by menadione and benzo(a)-pyrene-3,6-quinone in cultures of adult rat hepatocytes and human fibroblasts. Toxicology Letters, 1985, 28, 37-47.	0.4	30
131	Alterations in intracellular thiol homeostasis during the metabolism of menadione by isolated rat hepatocytes. Archives of Biochemistry and Biophysics, 1984, 235, 334-342.	1.4	409
132	Menadione-induced cytotoxicity is associated with protein thiol oxidation and alteration in intracellular Ca2+ homeostasis. Archives of Biochemistry and Biophysics, 1984, 235, 343-350.	1.4	372